[JPM 2026] Classys highlights K-aesthetic growth at JPMorgan

No Kyung-min 2026. 1. 15. 14:41
음성재생 설정 이동 통신망에서 음성 재생 시 데이터 요금이 발생할 수 있습니다. 글자 수 10,000자 초과 시 일부만 음성으로 제공합니다.
글자크기 설정 파란원을 좌우로 움직이시면 글자크기가 변경 됩니다.

이 글자크기로 변경됩니다.

(예시) 가장 빠른 뉴스가 있고 다양한 정보, 쌍방향 소통이 숨쉬는 다음뉴스를 만나보세요. 다음뉴스는 국내외 주요이슈와 실시간 속보, 문화생활 및 다양한 분야의 뉴스를 입체적으로 전달하고 있습니다.

Kim Lae-hee (third from left), chief marketing officer of Classys, speaks during a panel session at the 44th JPMorgan Healthcare Conference in San Francisco on Wednesday. (Classys)

South Korean medical aesthetics company Classys said Thursday it highlighted the growth potential of Korean aesthetic medicine on the global stage and its leadership in energy-based devices during a K-beauty-themed panel session at this year’s JPMorgan Healthcare Conference.

Classys became the first Korean company to join the newly introduced panel titled “Beyond K-Beauty” at the San Francisco-based conference, the company said.

“There is growing demand in the global aesthetics market for treatments that are less painful, highly effective and capable of delivering natural results with minimal downtime,” said Kim Lae-hee, chief marketing officer of Classys.

“Classys offers a comprehensive portfolio of optimized technologies across the EBD spectrum, including high-intensity focused ultrasound, monopolar radiofrequency and microneedle RF, and is now aggressively expanding into the at-home beauty device market.”

In November 2025, the company launched its beauty device, Lift2Glow, aiming to bring its proven medical-grade technology to a premium consumer product lineup.

Mark Halsey, a US-based dermatologist and panelist, praised the company’s flagship products such as Everes and Quadessy for driving high patient satisfaction. “Everes delivers comfortable yet highly effective improvements in facial volume and elasticity,” he said. “For physicians, it is quick and easy to administer, setting a new standard in the radiofrequency device category.”

According to the company, the panel session also showcased Classys’ ability to drive customer loyalty through a recurring revenue model, translating the potential of K-aesthetic medicine into measurable results.

“We are pursuing bold global marketing initiatives to enhance brand equity and deepen patient engagement, while scaling our international business with the goal of reaching $1 billion in revenue and operating margins exceeding 50 percent by 2030,” Kim added.

Classys posted revenue of 242.9 billion won in 2024, up 34.9 percent on-year, with third-quarter revenue climbing 40 percent to 83 billion won in 2025.

Copyright © 코리아헤럴드. 무단전재 및 재배포 금지.